Dual HER2 blockade with trastuzumab and pertuzumab has become the most preferred therapeutic option for patients with node‐positive, HER2‐positive breast cancer, with clinical trials demonstrating its superiority to single HER2 blockade in terms of pCR rate9, 10 and disease‐free survival.13 This evidence concerns the gene ERBB2 and breast cancer.